Text Size

Model 20066 Left Ventricular (LV) Lead Study

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Medtronic Cardiac Rhythm Disease Management
ClinicalTrials.gov Identifier:
NCT01365234
First received: May 25, 2011
Last updated: December 3, 2012
Last verified: December 2012
History of Changes

May 25, 2011
December 3, 2012
July 2011
July 2013   (final data collection date for primary outcome measure)
Number of implant procedure related and lead-related complications in the first month post-implant [ Time Frame: One Month ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01365234 on ClinicalTrials.gov Archive Site
  • Success rate of the Model 20066 lead [ Time Frame: Within 24 hours of procedure initiation ] [ Designated as safety issue: No ]
  • Cannulation time [ Time Frame: Within 24 hours of procedure initiation ] [ Designated as safety issue: No ]
  • Fluoroscopy Time [ Time Frame: Within 24 hours of procedure initiation ] [ Designated as safety issue: No ]
  • Model 20066 Lead Placement Time [ Time Frame: Within 24 hours of procedure initiation ] [ Designated as safety issue: No ]
  • Total Implant Time [ Time Frame: Within 24 hours of procedure initiation ] [ Designated as safety issue: No ]
  • Assessment of Lead Handling Characteristics [ Time Frame: Within 24 hours of procedure initiation ] [ Designated as safety issue: No ]
  • Electrical Performance-Tip Electrode: LV Voltage Threshold [ Time Frame: 12-month ] [ Designated as safety issue: No ]
  • Electrical Performance -Tip Electrode: Sensing [ Time Frame: 12-month ] [ Designated as safety issue: No ]
  • Electrical Performance -Tip Electrode: Pacing Impedance [ Time Frame: 12-month ] [ Designated as safety issue: No ]
  • Electrical Performance -Ring Electrode: LV Voltage Threshold [ Time Frame: 12-month ] [ Designated as safety issue: No ]
  • Electrical Performance -Ring Electrode: Sensing [ Time Frame: Within 24 hours of procedure initiation ] [ Designated as safety issue: No ]
  • Electrical Performance -Ring Electrode: Pacing Impedance [ Time Frame: 12-month ] [ Designated as safety issue: No ]
  • Summarize All Adverse Events [ Time Frame: 12-month ] [ Designated as safety issue: No ]
  • Summarize Final 20066 Lead Position [ Time Frame: Within 24 hours of procedure initiation ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Model 20066 Left Ventricular (LV) Lead Study
Model 20066 Left Ventricular (LV) Lead Study

Heart failure is a progressive disease that decreases the pumping action of the heart. This may cause a backup of fluid in the heart and may result in heart beat changes. When there are changes in the heart beat sometimes an implantable heart device is used to control the rate and rhythm of the heart beat. In certain heart failure cases, when the two lower chambers of the heart no longer beat in a coordinated manner, cardiac resynchronization therapy (CRT) may be prescribed. CRT is similar to a pacemaker. It is placed (implanted) under the skin of the upper chest. CRT is delivered as tiny electrical pulses to the right and left ventricles through three leads (flexible insulated wires) that are inserted through the veins to the heart. The purpose of this study is to evaluate a new lead for delivering energy to the left ventricle (bottom left chamber of the heart).
Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Heart Failure
Device: Pacing Lead
Implant and follow up of Model 20066 lead
Experimental: 20066 Lead
Non-randomized study. Intervention: Device: Pacing Lead
Intervention: Device: Pacing Lead
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
40
August 2013
July 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient meets CRT inclusion criteria as determined by local regulatory and/or hospital policy
  • Patient has signed and dated the study-specific informed consent form
  • Patient is 18 years of age or older
  • Patient is expected to remain available for follow-ups at the investigational center
  • Patient is willing and able to comply with protocol

Exclusion Criteria:

  • Patient has a previous complete atrial based biventricular CRT system
  • Patient has a previous LV lead implanted or previous implant attempt within 30 days of implant or ongoing AEs from previous unsuccessful attempt
  • Patient has known coronary venous vasculature that is inadequate for lead placement
  • Patient has unstable angina pectoris or has had an acute myocardial infarction (MI) within the past month
  • Patient has had a coronary artery bypass graft (CABG) or percutaneous transluminal coronary angioplasty (PTCA) within the past three months
  • Patient has chronic (permanent) atrial arrhythmias
  • Patient has contraindications for standard transvenous cardiac pacing (e.g., mechanical right heart valve)
  • Patient has had a heart transplant (patients waiting for heart transplants are allowed in the study)
  • Patient is enrolled in any concurrent drug and/or device study that may confound the results of this study
  • Patient has a terminal illness and is not expected to survive more than three months
  • Patient meets exclusion criteria required by local law (e.g. age, incompetence, pregnancy, breast feeding, etc).
  • Patient is unable to tolerate an urgent thoracotomy
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Canada,   Malaysia,   Sweden
 
NCT01365234
Model 20066
No
Medtronic Cardiac Rhythm Disease Management
Medtronic Cardiac Rhythm Disease Management
Not Provided
Principal Investigator: Raymond Yee, MD London Health Sciences Centre, London, Ontario, Canada
Medtronic Cardiac Rhythm Disease Management
December 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP